ClinConnect ClinConnect Logo
Search / Trial NCT02373761

A Prospective Radiostereometric Analysis (RSA) and Clinical Evaluation of the Triathlon Tritanium Total Knee Replacement

Launched by SCOTT SPORER · Feb 26, 2015

Trial Information

Current as of April 30, 2025

Unknown status

Keywords

ClinConnect Summary

Primary Hypothesis:

The investigators expect the tibial and patellar components of the Stryker Triathlon Tritanium knee to achieve adequate fixation to the underlying bone.

Secondary Hypotheses:

The investigators expect that there will be no continuous migration between one and two years post-operative in the Triathlon Tritanium components.

The investigators expect to see a correlation between radiolucent lines and migration characteristics using RSA.

The investigators expect that inducible displacement exams taken at 2 years post-operative will be able to distinguish between patients ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Symptomatic osteoarthritis of the knee indicating surgical intervention
  • Scheduled to undergo a total knee arthroplasty
  • Patients between the ages of 18 and 80, inclusive
  • Patient is a candidate for Triathlon Tritanium cementless knee components implanted in accordance with product labeling
  • Exclusion Criteria:
  • Significant co-morbidity affecting ability to ambulate
  • Prior arthroplasty, patellectomy or osteotomy with the affected knee
  • Active or prior infection of the affected knee
  • Morbid obesity (BMI \> 40)
  • Medical condition precluding major surgery
  • Severe osteoporosis
  • Neuromuscular impairment
  • Pregnancy
  • Inability to give informed consent
  • Inability to return for follow-up visits for a minimum of two years after surgery
  • Currently participating in any other surgical intervention study
  • Known allergy to metals
  • Flexion contracture greater than 15°
  • Extension lag greater than 10°
  • Tibial subluxation greater than 10 mm on standing AP radiograph
  • Lateral or medial collateral ligament instability (\> 10° varus/valgus)
  • Leg length discrepancy greater than 10 mm

About Scott Sporer

Scott Sporer is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With extensive experience in the design and management of clinical trials, Scott Sporer emphasizes rigorous scientific methodologies and ethical standards to ensure the integrity and reliability of research findings. The organization collaborates with leading healthcare professionals and institutions, leveraging cutting-edge technology and data analytics to streamline trial processes and enhance participant engagement. Through a patient-centered approach, Scott Sporer strives to contribute to the development of safe and effective treatments across various therapeutic areas.

Locations

Winfield, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Scott Sporer, MD

Principal Investigator

Central DuPage Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials